be used to treat patients with recurrent nonfunctioning adenomas and may be used as a primary treatment in a group of patients for whom resection as an initial treatment is considered unwise. 3, [9] [10] [11] [12] 14, 21, 22, 24, [29] [30] [31] 33, 35, 45, 47 In this study, we present our updated outcomes of 140 patients with nonfunctioning pituitary macroadenomas treated using GKS, and we assess factors predictive of tumor control, neurological decline, and hypopituitarism.
Methods
This study was a retrospective analysis of a prospectively maintained, IRB-approved database. Between June 1989 and March 2010, 140 patients with nonfunctional (nonsecretory) pituitary macroadenomas were treated at the University of Virginia using GKS. The diagnosis was confirmed either by tissue pathology or characteristic findings for pituitary adenomas on neuroimaging studies. 7 Gamma Knife surgery was used for patients with recurrent adenomas after prior resection in 127 cases. Gamma Knife surgery was used as an initial treatment in 13 patients who were not candidates for primary surgical treatment related to their advanced age, high operative risks based on medical comorbidities, and/or refusal of microsurgical resection.
Radiosurgical Technique
Our radiosurgical technique has been previously described. 35, 38, 46 Radiosurgery was performed using the Leksell Gamma Unit (Elekta Instruments) model U from 1989 to 2001, and model C from 2001 to 2010. Dose planning was performed by a neurosurgeon using stereotactic MRI with a goal of achieving optimal tumor irradiation while minimizing exposure to surrounding structures. GammaPlan software (Elekta) was used for treatment planning. Pre-and postcontrast T1-weighted MR images were obtained with a slice thickness of 1.2 mm. Fat saturation stereotactic imaging was also obtained.
Patients underwent placement of a stereotactic Leksell G-frame in the operating room. During frame placement anesthesia was induced in patients and monitored by an anesthesiologist. Stereotactic MRI was then obtained for treatment planning. Pre-and postcontrast thinslice (1-mm) axial and coronal MRI sequences were obtained. Fat suppression imaging was also obtained at the time of GKS. When MRI could not be obtained because of medical contraindications (such as in patients with a cardiac pacemaker), a thin-slice stereotactic CT scan was obtained with and without contrast administration. Radiosurgical dose plans were formulated under the direction of a neurosurgeon in conjunction with a medical physicist and radiation oncologist. 39 
Clinical and Radiological Follow-Up
Just prior to GKS, patients underwent a neurological evaluation and comprehensive endocrine evaluation. Basal serum levels of cortisol, free thyroxine, and prolactin were evaluated. Testosterone and growth hormone assessment was conducted based on clinical relevance. Pituitary insufficiency was defined as a condition requiring hormone replacement. Patients underwent stereotactic MRI or CT on the day of GKS. This information served as the baseline data to which follow-up information was compared.
Patients were commonly followed clinically and radiologically every 6 months for the 1st year, annually until 5 years after radiosurgery, and every 2 years thereafter. At each follow-up visit, a neurological examination including ophthalmological assessment was performed to evaluate for new neurological deficits, and neuroimaging studies were reviewed to assess the tumor's response. Endocrine evaluations were performed at the same time points as radiological and neurological follow-up. All follow-up was performed at the University of Virginia, unless the patient was unable to travel to our institution. In such cases, the referring physician performed the follow-up and provided documentation of the patient's neurological status as well as follow-up imaging.
All neuroimaging studies were reviewed by a neurosurgeon and a neuroradiologist at the University of Virginia. Imaging outcome was determined by the last available examination. 37 A decrease or increase in tumor size was defined as a 15% or greater change in tumor volume as compared with the volume at the time of GKS. 37 To make this determination of tumor size, the tumor was outlined on radiographic images, and serial volumetric calculations were performed using the ImageJ program (NIH; http://rsb.info.nih.gov/ij/) in all patient imaging studies. 37 Any patient with tumor progression of more than 15% was considered a treatment failure, even if this progression stabilized with further GKS or microsurgery.
Statistical Analysis
Data are presented as median or mean and range for continuous variables, and as frequency and percentage for categorical variables. Statistical analyses of categorical variables were performed using the chi-square test, Fisher exact test, and Mantel-Haenszel test for linear association, as appropriate. Statistics involving means were calculated using the unpaired Student t-test, both with and without equal variance (Levene test) as necessary, and the Wilcoxon rank-sum test when variables were nonnormally distributed. Kaplan-Meier plots of tumor progression were computed. The following factors were assessed for their ability to predict tumor progression, new or worsening neurological function, and new or worsening endocrinopathy: patient age, patient sex, tumor location, tumor volume, maximum tumor diameter, length of follow-up, previous surgery, number of isocenters, margin dose, maximum dose, percentage isodose line, and isodose volume. Factors predictive of tumor progression (p < 0.15) were entered into Cox regression analysis to assess hazard ratios. 1 Additionally, clinical covariates predicting new or worsening neurological function or new endocrinopathy with a univariate p value < 0.15 were included in multivariable logistic regression analysis. Clinically significant variables and interaction expansion covariates were further assessed in both Cox and logistic multivariable analysis as deemed relevant. Probability values ≤ 0.05 were considered statistically significant.
Results

Patient Characteristics
Of the 140 patients, 78 (56%) patients were male, and 62 (44%) were female ( Table 1 ). The median patient age at the time of GKS was 51 years (range 21-82 years). Thirteen patients (9%) had GKS as an initial intervention, and 127 (91%) underwent at least 1 open resection prior to GKS. In 10 patients the resection was followed by conventional radiotherapy, but the tumor progressed after radiotherapy, and GKS was undertaken.
Tumor Characteristics
All tumors were initially macroadenomas. The median tumor volume was 3.7 cm 3 (mean 5.6 cm 3 , range 0.6-35 cm 3 ) at the time of GKS. In 85 (61%) of 140 patients, the tumor had a suprasellar component, and 55 (39%) of the 140 had cavernous sinus involvement.
Gamma Knife Surgery Dosimetry
The median maximum dose to the tumor was 36 Gy (range 15-70 Gy); the median tumor margin dose was 18 Gy (range 6-25 Gy). The median number of isocenters used was 7 (range 1-26; Table 2 ). The maximum dose to the visual pathways (optic apparatus) was typically limited to 1-4 Gy (mean 2.5 Gy). In a few cases in which the tumors were close to the optic pathway, only a small amount of nerve (< 1%) received doses greater than 8 Gy. Whenever necessary, shielding was used to limit the radiation dose to the optic apparatus.
Radiological Outcome
Tumor volume remained stable or decreased in 113 (90%) of 125 patients with available follow-up imaging. Kaplan-Meier analysis demonstrated radiographic progression-free survival at 2, 5, 8, and 10 years to be 98%, 97%, 91%, and 87%, respectively (Fig. 1) . The median duration until tumor progression was 14.5 years. There was no significant difference in the rate of tumor progression in those with a history of surgery (9.7%) compared with those who received only GKS (8.3%; p = 1.0). Over time, there was no difference in rates of tumor control, and this did not vary by Gamma Knife unit. The remission rate was 88% after radiosurgery performed using the Leksell Gamma Unit model U from 1989 to 2001, compared to 93% with the model C used from 2001 to 2010 (p = 0.285). There was no significant difference in tumor control rates between patients treated with 12-20 Gy versus those treated with more than 20 Gy. Four (50%) of 8 patients receiving less than 12 Gy showed poor tumor control compared with 8 (7.1%) of 113 receiving greater than 12 Gy (p = 0.016). The mean marginal radiosurgical dose was lower in patients with tumors larger than 5 cm 3 (15.7 ± 4.6 Gy) compared with patients with tumors 5 cm 3 or smaller (19.0 ± 5.0 Gy; p < 0.001). In multivariate analysis, a tumor volume more than 5 cm 3 (HR = 5.0, 95% CI 1.5-17.2, p = 0.023) was the only factor predictive of tumor growth (Fig. 2) .
Eleven patients required further therapy after the initial GKS. Of these 11 patients, 7 underwent a subsequent transsphenoidal resection. Four patients underwent repeated GKS at 35, 37, 61, and 108 months after the first * Data presented as median ± SD (range).
Fig. 1.
Graph of radiographic tumor progression-free survival over time.
treatment: 2 repeat GKSs for regrowth of the tumor and 2 for new lesions involving the contralateral parasellar space. Two new lesions and 1 tumor regrowth decreased in size after the second GKS, whereas the imaging follow-up data were not available in the fourth patient.
Clinical Outcome
A new or worsening cranial nerve deficit occurred in 16 (13.7%) of 117 patients with follow-up data on specific cranial nerve function. These deficits included visual decline in 15 patients (12.8%) and sixth cranial nerve palsy in 1 patient. All patients with cranial nerve worsening had demonstrable tumor progression on follow-up neuroimaging. In multivariate analysis, tumor volume greater than 5 cm 3 (OR = 3.7, 95% CI 1.2-11.7; p = 0.025) and pre-GKS hypopituitarism (OR = 7.5, 95% CI 1.1-60.8; p = 0.05) were predictive of a new or worsened neurological deficit. There were no differences in neurological deficits over time: 10 (17%) of 60 patients experienced deficits prior to 2001, compared with 6 (11%) of 57 after 2001 (p = 0.328). There was no significant association between marginal dose as a continuous or dichotomized variable in relation to rates of new or worsening deficits. There was no significant difference (p = 0.229) in mean dose to the optic apparatus in those patients who did (3.5 ± 2.4 Gy) and did not (4.5 ± 2.7 Gy) experience visual decline.
Endocrine Outcome
Basal serum levels of cortisol, free thyroxine, and prolactin were evaluated in all patients. Gonadal function was assessed in men clinically and by measuring serum testosterone. The loss of menses in premenopausal women indicated gonadotropin failure.
At the time of GKS, 51 of 140 patients had cortisol deficiency, 62 had thyroid deficiency, 47 had sex hormone deficiency, 16 had growth hormone deficiency, and 11 had diabetes insipidus ( 
Other Serious Complications
In this series, no cases of radiosurgically induced neoplasia, brain parenchymal necrosis, or stroke were noted following GKS.
Discussion
Pituitary adenomas are common lesions found in 10%-27% of the general population. 4, 43 Although they are not malignant, the cumulative morbidity associated with treating these lesions can be significant over a patient's lifetime. Stereotactic radiosurgery has become a common adjuvant or rescue treatment for patients with recurrent or residual nonfunctioning pituitary adenomas. Leksell 19 reported the first series in which radiosurgery was performed to treat 37 patients with nonfunctioning pituitary adenomas. Stereotactic radiosurgery offered a focal, minimally invasive treatment for nonfunctioning pituitary adenomas. Since that initial study, the results of stereotactic radiosurgery have largely been detailed in single-center retrospective studies (Table 3) .
Tumor Control
Stereotactic radiosurgery affords a high rate of tumor control for nonfunctioning pituitary adenomas. Most large radiosurgical series demonstrate a tumor control rate of approximately 90%. 10, 12, 15, 24, 29, 36 The current series demonstrates an overall tumor control rate of 90% and an actuarial 5-year progression-free survival rate of 97%. Tumor control was directly related to GKS treatment volume. Thus, these data underscore the value of microsurgical resection prior to GKS for macroadenomas.
In other patient series, the most significant considerations have been sample size and length of follow-up. A larger sample size provides a more accurate representa- tion of these patients, and a long follow-up permits us to discern the natural history of these typically slow-growing tumors from treatment effect. Therefore, it is essential that the course of these lesions is followed up for an adequate duration. This point is underscored by the work of Mingione et al., 24 who demonstrated an association between longer follow-up and a propensity of nonsecretory pituitary macroadenomas to either grow or decrease. Given these data, the most comparable report published to date comes from Park et al., 29 who noted a 90% tumor control rate in 125 patients, with a mean follow-up of 62 months. Gopalan et al. 8 reported on long-term outcomes of GKS for nonfunctioning adenomas and demonstrated a tumor control rate of 83% with a median follow-up of 95 months.
Neurological Outcome
Radiosurgery afforded preservation of neurological function in 86.3% of patients. Visual decline was the most common deficit, and all patients had tumor progression at the time of neurological decline. The most common neurological deficit was visual decline. Macroadenomas larger than 5 cm 3 and previous hypopituitarism were predictors of new neurological decline. Intuitively, larger adenomas may be in close proximity to radiation-sensitive structures, such as the optic apparatus, that may limit delivery of an ideal dose, and previous hypopituitarism may also be a surrogate marker for tumor size. Park et al. 29 and Gopalan et al. 8 also noted that tumor volume was a predictor of delayed hypopituitarism.
Radiosurgery is believed to involve a low but measurable risk of neurological morbidity for patients with pituitary adenomas. Park et al. 29 noted a 2.4% incidence of new neurological decline after GKS in patients with nonfunctional pituitary adenomas. The optic apparatus is generally believed to be the most radiosensitive cranial nerve. Radiation tolerance for the second cranial nerve has been reported to range from 8 Gy to 12 Gy and depends on the volume treated in single-dose radiosurgery. 17, 18, 23, 41 There is little known about the tolerance of the cranial nerves of the cavernous sinus. Leber et al. 17, 18 did not find any radiosurgery-induced neuropathies in patients with cavernous sinus pathology after GKS doses ranging from 5 Gy to 30 Gy. In contrast, Tishler et al. 41 reported a 13% (8/62) incidence of deficits from the third to the sixth cranial nerve in patients with cavernous sinus pathology undergoing radiosurgery, but they could not determine a critical GKS dose. Similarly, we did not encounter a significant relationship between GKS dose and new or worsening deficits. 
Complications
Reported rates of hypopituitarism after radiosurgery range from 0% to as high as 72%, depending on the series and pathology addressed. 10, 13, 20, 32, 34, 35 The current patient series demonstrated an overall risk of hypopituitarism of 30.3%. Our analysis did not identify any predictors for hypopituitarism. The study by Park et al. 29 found a lower incidence of hypopituitarism (24%) with a median time to occurrence of 24 months. This study did identify previous radiation as a risk factor for developing hypopituitarism. The work of Gopalan et al. 8 has underscored the need for long-term endocrine follow-up, showing that 39% (19/48) of patients developed delayed hypopituitarism between 57 and 201 months. Previous reports have suggested that the radiation dose to the pituitary stalk or functioning gland may relate to radiosurgically induced hypopituitism. 6, 44 This suggestion has prompted some investigative groups to perform a hypophysopexy to limit the dose to the functioning gland, but whether this technique is useful has yet to be clearly demonstrated. 40 The critical radiation dose to the functioning pituitary gland has yet to be identified. However, it has been shown that hypopituitarism develops gradually and can be detected by endocrine evaluation so that patients can begin replacement therapy. 42 Thus, when weighing the competing interests of tumor progression and hypopituitarism, delivering an ideal radiation dose to the tumor should be the primary concern, with the expectation of regular follow-up evaluation.
8,42
Experience Over Time
There was a trend toward decreased endocrine deficits following GKS over time. There was also a trend toward decreased mean marginal dose over time, which may partially explain lower rates of endocrine dysfunction. The overall higher GKS doses used in this study compared with a number of other studies (Table 3 ) are in part due to higher doses that were originally used for silent adrenocorticotropic hormone and thyroid-stimulating hormone tumors (those staining positively on immunohistochemistry but that were nonsecretory). These tumors were believed to be more resistant to GKS. Overall, there was no difference in the rates of tumor control or neurological deficits over time when comparing different GKS models.
Study Limitations
Although the current study represents the largest series of patients with nonfunctioning pituitary macroadenomas with a long mean follow-up duration, there are several weaknesses of the study that should be noted. This is a single-center analysis and thereby reflects the treatment biases of our institution and referral patterns. Furthermore, this is a retrospective analysis and is therefore inherently subject to bias. Our median follow-up was 4.2 years; thus we may have incompletely assessed delayed hypopituitarism, tumor control, and radiosurgeryinduced neoplasia.
Conclusions
This is the largest study of GKS for patients with nonfunctioning pituitary macroadenomas. We show that GKS affords a high rate of local tumor control with a low risk of new neurological injury. Stereotactic radiosurgery is generally used to treat those patients with recurrent or residual nonfunctioning adenomas after resection. 3, [9] [10] [11] [12] 14, 21, 22, 24, [28] [29] [30] [31] 33, 35, 45, 47 Hypopituitarism is the most common complication in these patients but typically occurs with select hormones and in few patients. New cranial nerve dysfunction and other more serious complications appear infrequent after GKS.
